对于FLT3-ITD突变阳性的AML，除了化疗和干细胞移植，还可以使用FLT3激酶抑制剂。FLT3抑制剂主要通过竞争性抑制FLT3受体中的ATP结合位点，导致细胞周期停滞和分化。迄今为止，在日本、欧洲和美国，已有多种FLT3抑制剂被临床批准作为单药治疗或与传统化疗药物联合治疗。2017年Midostaurin（米哚妥林）被美国FDA批准与标准化疗联合...
These data suggest that different classes of activating mutation of the same tyrosine kinase receptor can be associated with markedly different clinical outcomes. FLT3 ITDs are associated with a poor prognosis and FLT3 TKD mutations with a relatively good prognosis. This unexpected genotype-phenotype ...
The favourable prognosis associated with CEBPA mutation in AML is now known to be related to biallelic mutations only; therefore, biallelic mutation is now required for assignment to this category. 【翻译】目前已知,急性髓系白血病伴CEBPA...
[2] Halahleh K , Taqash A , Abdelkhaleq H , et al. Analysis of FLT3-activating mutations in patients with acute myelogenous leukemia in Jordan: association with FAB subtypes and identification of subgroups with poor prognosis[J]. Clinical Lymphoma, Myeloma and Leukemia, 2021(23). [3] Blood...
with the internal tandem duplication (ITD) representing the most common type ofFLT3mutation (FLT3-ITD; approximately 25% of all AML cases).FLT3-ITD is a common driver mutation that presents with a high leukemic burden and confers a poor prognosis in patients with AML. The prognostic value of...
AML with biallelic mutation of CEBPA is associated with a favourable prognosis, similar to that of AML with inv(16)(p13.1q22) or t(8;21)(q22;q22.1). The influence of FLT3―ITD and GATA2 mutations on prognosis in this group is currently unclear.AML伴CEBPA双等位基因突变者预后良好，与...
AML with mutated NPM1 typically shows a good response to induction therapy. Cases with a normal karyotype, in the absence of FLT3―ITD mutation, have a characteristically favourable prognosis. Younger patients with a normalkaryotype and no FLT3―...
These contain internal tandem duplication (ITD) and D835 mutation. The studies show that FLT-3 mutations are related to AML subgroups, leukocyte count, blast increase, response to treatment and patients' prognosis.Materials & Methods: 70 AML patients were selected after exact diagnosis, and their...
An activating mutation of FLT3 is the most frequent genetic alteration associated with poor prognosis in acute myeloid leukemia (AML). Although many FLT3 inhibitors have been clinically developed, no first-generation inhibitors have dem... T Yamaura,T Nakatani,K Uda,... - 《Blood》 被引量: 1...
异基因造血细胞移植(HCT)改善了携带FLT3内部串联重复突变(FLT3-ITD)的急性髓系白血病(AML)患者的预后。这部分患者在HCT后常规接受FLT3抑制剂治疗,但支持这一治疗的证据有限。因此,研究者开展了一项FLT3抑制剂吉瑞替尼用于HCT后维持治疗的随机...